Story
Nebius Stock Jumps Over 27% on Billion-Dollar AI Deal and Strong Sector Demand

Summary
Shares of the GPU-focused cloud provider surged after it secured a major long-term revenue contract and benefited from a sector-wide lift following Microsoft's strong cloud earnings.
Shares of Nebius (NBIS) surged as much as 28.7% in morning trading, driven by a confluence of positive factors including a major new client contract, the removal of a key selling overhang, and strong sector-wide demand for artificial intelligence infrastructure.
Key Catalysts Behind the Move
The rally was ignited by several company-specific and market developments. According to a report from Investing.com, the primary drivers include:
- A major client agreement: Nebius disclosed a multi-year deal to provide more than $1 billion of GPU-based computing capacity to Reflection AI. The contract, which runs through 2029, provides investors with contracted, long-duration revenue, signaling strong enterprise demand for the company's services.
- Relief from selling pressure: The news followed reports that the Situational Awareness fund had collapsed, which may have been responsible for recent forced selling in the stock. The end of this selling pressure likely removed a significant headwind for the share price.
Microsoft Earnings Provide Sector-Wide Lift
A powerful tailwind came from technology giant Microsoft, which reported fiscal fourth-quarter results that beat expectations. Microsoft's Azure cloud revenue growth accelerated to 43%, with the division crossing $100 billion in annual revenue for the first time.
AdAs Nebius operates as a specialized GPU-focused "neocloud" provider, Microsoft's strong performance was seen by investors as direct validation of sustained enterprise demand for the entire AI compute ecosystem. This positive sentiment was amplified by a broad market rally, with the Nasdaq Composite climbing 2.3%.
Technical and Sentiment Backdrop
The sharp move also occurred from a technically oversold position. Nebius shares had declined more than 30% from their mid-July highs, closing near $148 in the prior session, which attracted dip-buyers on Tuesday's positive news flow.
Analyst sentiment was already constructive heading into the session, with a consensus Buy rating on the stock. Northland Capital Markets holds one of the highest price targets at $410, according to the report. The combination of fundamental catalysts and a favorable technical setup propelled the stock to an intraday high of $195.89.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.